Soluble Fms-like tyrosine kinase
Overview
Summary

Epidemiology

Fms-like tyrosine kinase (Flt-1), also
known as Vascular Endothelial GrowthFactor Receptor 1 (VEGFR-1), is amembrane
receptor
fordifferent
members of the vascular endothelial
growth factor family like VEGF-A,
VEGF-B and Placental Growth Factor(PlGF). The soluble form of VEGFR-1,
also known as sFlt-1, comprises the656
N-terminal
residuesofthereceptor, followed by a specific 30
amino acid tail at its C-terminus that is
produced in endothelial cells.

In clinical laboratory settings, measuring
the circulating levels of sFlt-1 is crucial
in diagnosing preeclampsia, along withother medical parameters. Preeclampsia
is responsible for 10-15% of maternal
deaths worldwide, according to theWorld Health Organization (WHO)1.
Elevated levels of sFlt-1 have beenfound in hypoxia or impaired perfusionof the placenta. The increased levels ofsFlt-1 have a detrimental effect that
could have a relation with the clinicaland laboratory observations seen inpreeclampsia.

sFlt-1 CLIA RUO prototype
Assay SchemeQuantitative detection of soluble FMS-like tyrosine kinase in human serum/plasma
Assay scheme
Two-step assay (quantitative)

(I)

(II)
TriggerssFlt-1

RLUs

PMPsSample

Conjugate

Magnetic particle
coated with Werfen
anti-sFlt-1 mAbserum/plasma

Werfen anti-sFlt-1-isoluminol

1 World Health Organization (WHO). (2019). Maternal Mortality. Retrieved from https://www.who.int/news-room/fact-sheets/detail/maternal-mortality

Dose-response in sFlt-1 RUO prototype
CalibratorSample

pg/mL*RLU’s

S0S1S2S3S4S5S601841,263
10,18012,70326,89085,000310
1,407
13,326
136,304
164,051
321,657
729,140*Concentration of the calibrator samples obtained with areference method
Figure 1. Anti-sFlt-1 mAb (1) was used for coating PMPs and Anti-sFlt1 mAb (2) labeled with Iso-luminol was used as a detector on CLIA
assay. A sFLT1 recAg (Werfen Biomaterial) diluted in serum at different
concentrations was used as a calibrator sample set. Dose response
curve shows reactivity of the different calibrator samples plottedagainst the concentration obtained with a reference method (measuredin pg/mL).

Assay Range

S6/S0

1,299

Table 1. Numerical results dose-response calibration curve.
Signal-to-noise and assay range performance evaluation.

Method Comparison of sFlt-1 RUO prototype vs reference assay

Figure 2 & 3. Method comparison for performance evaluation – Pregnant women with and without risk of preeclampsia. Quantitative correlationof sFLT1 concentration obtained in sFLT1 Werfen CLIA prototype of 40 individual serum samples compared to the concentration determined withthe reference method.

Werfen’s Biomaterial offering
Anti-sFlt-1 mAb 1 (ref 3000-7060)
Storage: -70ºC
Source: Hybridoma cell Line
Storage buffer: MES , NaCl pH 6,0
Purification method: Protein A
Protein concentration:1 mg/mL
Preservative: None

Anti-sFlt-2 mAb 2 (ref 3000-7061)
Storage: -70ºC
Source: Hybridoma cell Line
Storage buffer: MES , NaCl pH 6,0
Purification method: Protein A
Protein concentration:1 mg/mL
Preservative: None

This product is in R&D Stage and is for “Investigation / Research Use Only”. The content within this brochure is provided for
informational purposes.
Contact oem@werfen.com for further technical information and product availability
Version 1 Dec-2023